Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9517441 | 0.98 | DUT (0.37) | DUT | |
| SCHEMBL97731 | 0.98 | DUT (0.37) | DUT | |
| SCHEMBL9517422 | 0.98 | DUT (0.37) | DUT | |
| SCHEMBL94712 | 0.93 | DUT (0.39) | DUT | |
| SCHEMBL8063404 | 0.88 | DUT (0.43) | DUT | |
| SCHEMBL9007756 | 0.85 | DUT (0.42) | DUT | |
| SCHEMBL14245094 | 0.85 | DUT (0.42) | DUT | |
| SCHEMBL27241092 | 0.85 | DUT (0.42) | DUT | |
| SCHEMBL95573 | 0.83 | DUT (0.34) | DUT | |
| SCHEMBL28000694 | 0.81 | DUT (0.33) | DUT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107954933-B | 2-azabicyclo [4.2.0] octane compounds and synthesis and application thereof | 浙江大学 | 2020-10-23 | — | — | CN | claimed |
| CN-114245798-A | CGRP antagonist compounds | 赫普泰雅治疗有限公司 | 2022-03-25 | — | — | CN | disclosed |
| CN-107954933-B | 2-azabicyclo [4.2.0] octane compounds and synthesis and application thereof | 浙江大学 | 2020-10-23 | — | — | CN | disclosed |
| US-8362252-B2 | Carbostyril compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-01-29 | — | — | US | disclosed |
| EP-1797082-B1 | CARBOSTYRIL COMPOUND | OTSUKA PHARMA CO LTD (JP) | 2012-08-29 | — | — | EP | disclosed |
| EP-2426128-A1 | Carbostyril compound | Otsuka Pharmaceutical Co., Limited (JP) | 2012-03-07 | — | — | EP | disclosed |
| US-20100261705-A1 | CARBOSTYRIL COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. | 2010-10-14 | — | — | US | disclosed |
| US-7777038-B2 | Carbostyril compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2010-08-17 | — | — | US | disclosed |
| US-7723514-B2 | Method of preparing a 5H-dibenz(b,f)azepine-5-carboxamide | TARO PHARMACEUTICALS U.S.A., INC. (US) | 2010-05-25 | — | — | US | disclosed |
| US-20090326008-A1 | NF-kappa B Inhibitor | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2009-12-31 | — | — | US | disclosed |
| US-20060241292-A1 | Method of preparing a 5H-dibenz(b,f)azepine-5-carboxamide | TARO PHARMACEUTICALS USA, INC (US) | 2006-10-26 | — | — | US | disclosed |
| US-7091339-B2 | Method of preparing a 5H-dibenz(b,f)azepine-5-carboxamide | TARO PHARMACEUTICALS USA, INC. (US) | 2006-08-15 | — | — | US | disclosed |
| WO-2006035954-A1 | CARBOSTYRIL COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-04-06 | — | — | WO | disclosed |
| EP-1482924-A4 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK FROSST CANADA INC (CA) | 2006-03-08 | — | — | EP | disclosed |
| EP-1513816-A2 | METHOD OF PREPARING A 5H-DIBENZ(B,F)AZEPINE-5-CARBOXAMIDE | TARO PHARMACEUTICALS U.S.A., INC. (US) | 2005-03-16 | — | — | EP | disclosed |
| EP-1482924-A2 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK FROSST CANADA INC. (CA) | 2004-12-08 | — | — | EP | disclosed |
| US-20040044200-A1 | Method of preparing a 5H-dibenz(b,f)azepine-5-carboxamide | TARO PHARMACEUTICALS U.S.A. | 2004-03-04 | — | — | US | disclosed |
| WO-2003106414-A2 | METHOD OF PREPARING A 5H-DIBENZ[B,F]AZEPINE-5-CARBOXAMIDE | TARO PHARMACEUTICALS U.S.A., INC. (US) | 2003-12-24 | — | — | WO | disclosed |
| WO-2003075836-A2 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK FROSST CANADA & CO. (CA) | 2003-09-18 | — | — | WO | disclosed |
| EP-0140307-A2 | 7-Oxabicycloheptane ethers | E.R. Squibb & Sons, Inc. (US) | 1985-05-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090326008-A1 | NF-kappa B Inhibitor | NFKBIA, NFKB2, IKBKB | DUT 4147/4885 |
| US-20040044200-A1 | Method of preparing a 5H-dibenz(b,f)azepine-5-carboxamide | KCNH1, KCNMB1, KCNMB4 | DUT 447/4885 |
| US-20060241292-A1 | Method of preparing a 5H-dibenz(b,f)azepine-5-carboxamide | C5, C1S, CBR3 | DUT 482/4885 |
| US-20100261705-A1 | CARBOSTYRIL COMPOUND | GTF2F1, F3, GTF2F2 | DUT 4729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.